Cardiovascular responses to glibenclamide during endotoxaemia in the pig.
The effects of blockading the ATP-sensitive potassium channel (K+ATP channels) on endotoxin-induced vascular derangements was studied. Escherichia coli endotoxin was infused (20 micrograms/kg per h) intravenously for 180 min into anaesthetized, mechanically ventilated, indomethacin-treated pigs. After 150 min of endotoxaemia, glibenclamide (a K+ ATP channel blocker) was infused intravenously at 2 mg/kg per min for 5 min. The cardiovascular parameters were recorded before (control), every 30 min up to 150 min during endotoxaemia, and then at 5, 15 and 30 min after administration of glibenclamide. Infusion of endotoxin reduced the systemic arterial pressure to 60.6% +/- 3.7% (p < 0.01) and increased the pulmonary arterial pressure by 75.9% +/- 11.0% (p < 0.01) of the control values. Within 5 min, infusion of glibenclamide transiently but significantly reversed the systemic hypotension by raising the systemic vascular resistance, whereas the increased pulmonary arterial pressure was further augmented. Glibenclamide infusion did not influence the cardiac output. Within 30 min, the cardiovascular parameters had returned to the values induced by endotoxin, except for the systemic vascular resistance. Infusion of glibenclamide into normal pigs did not change the systemic pressure or resistance, but the pulmonary pressure and resistance were augmented transiently. These data suggest that, in pigs, the ATP-sensitive K+ channels may be one factor playing a role in the vascular changes due to endotoxaemia, especially in the systemic circulation.
Vanelli
G
G
Institute of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Milan, Italy.
Hussain
S N
SN
Dimori
M
M
Aguggini
G
G
D000255:Adenosine Triphosphate / Q000502:physiology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000187:drug effects*; D019806:Cromakalim; D019446:Endotoxemia / Q000503:physiopathology / Q000662:veterinary*; D004731:Endotoxins / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007260:Infusion Pumps / Q000662:veterinary; D007262:Infusions, Intravenous / Q000379:methods / Q000662:veterinary; D007267:Injections / Q000379:methods / Q000662:veterinary; D008297:Male; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology; D013552:Swine; D013553:Swine Diseases / Q000503:physiopathology*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D000959:Antihypertensive Agents; D001578:Benzopyrans; D004731:Endotoxins; D007004:Hypoglycemic Agents; D015221:Potassium Channels; D011758:Pyrroles; D019806:Cromakalim; D000255:Adenosine Triphosphate; D005905:Glyburide